Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and ...

Vertex Pharmaceuticals Inc. hit a major milestone on Thursday when the U.S. Food and Drug Administration approved its ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Sanofi Healthcare India receives marketing authorization for Rezurock, a new treatment for chronic graft-versus-host disease ...

The French drugmaker said it had entered a mandate with an “investment service provider”, with the purchase occurring between ...

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

Sanofi Healthcare India has obtained marketing authorization for Rezurock, a drug for treating Chronic graft versus host ...

The Indian subsidiary of French pharma major Sanofi has received marketing authorization for Rezurock (belumosudil tablets) in India.

Sanofi Healthcare India has received marketing authorization for Rezurock, a drug for chronic graft versus host disease (cGVHD). Approved by USFDA and CDSCO, Rezurock offers a new treatment for ...

Sanofi Healthcare India receives marketing authorization for Rezurock (Belumosudil), a new treatment for Chronic Graft-versus-Host Disease (cGVHD) in adults and adolescents.

Sanofi has received China’s NMPA approval for the use of Sarclisa, combined with a standard-of-care regimen, for treating ...